The findings offer preliminary evidence underscoring the potential role of DS8201 in managing advanced HER2-amplified lung metastases from breast cancer, particularly in cases that have progressed after initial HER2-targeted therapies. The gene discussed is ERBB2; the disease is breast cancer.